Inhibrx Biosciences Inc (INBX)

$35.65 +0.59 (1.67%)
Market Cap 516.39M
Revenue (ttm) 200,000.00
Net Income (ttm) 1.69B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 843,784.96%
Debt to Equity Ratio 1.45
Volume 112,200
Avg Vol 117,404
Day's Range N/A - N/A
Shares Out 14.49M
Stochastic %K 82%
Beta 0.51
Analysts Hold
Price Target $12.00

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma,...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 795 4220
Website: inhibrx.com
Address:
11025 North Torrey Pines Road, Suite 140, La Jolla, United States
highnihilism
highnihilism Oct. 1 at 9:29 AM
$UAN CVR Partners LP Trade Count: 10 | Total $: 6.1 K | 0.01 × 90-Day Avg $: 648 | Call $: 3.3 K | Put $: 2.8 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CRDU 2X Long $CRDO Daily ETF Trade Count: 3 | Total $: 3.4 K | 0.50 × 90-Day Avg $: 6.7 K | Call $: 3.3 K | Put $: 120 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $INBX Inhibrx Biosciences Trade Count: 11 | Total $: 4.9 K | 0.24 × 90-Day Avg $: 20.8 K | Call $: 3.2 K | Put $: 1.7 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $FDP Fresh Del Monte Produce Trade Count: 9 | Total $: 3.4 K | 0.35 × 90-Day Avg $: 9.9 K | Call $: 3.2 K | Put $: 202 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
highnihilism
highnihilism Sep. 16 at 7:44 PM
IWM: Russell 2000 → $REFI Chicago Atlantic Real Estate Finance $PLOW Douglas Dynamics $INBX Inhibrx Biosciences $VIR Vir Biotechnology $RXST Rxsight
0 · Reply
DriftScale
DriftScale Sep. 15 at 10:18 AM
$INBX Steady performer; incremental growth from new product launches
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 7:46 AM
$INBX Really good write-up that perfectly summarizes INBX's present situation. So if you want to bring your INBX knowledge up to date or just discover INBX, this is required reading. https://beyondspx.com/quote/INBX/inhibrx-biosciences-unpacking-the-post-spin-off-pipeline-and-technology-edge-nasdaq-inbx#analysis
0 · Reply
MacroMotif
MacroMotif Aug. 27 at 9:47 AM
$INBX gradually climbing, but watch for sharp reversals.
0 · Reply
JarvisFlow
JarvisFlow Aug. 22 at 1:01 PM
JMP Securities updates rating for Inhibrx Biosciences ( $INBX ) to Market Perform.
0 · Reply
mitchell5150
mitchell5150 Jul. 8 at 2:32 PM
$INBX Let’s go!!!!!
0 · Reply
TrendTrade8696
TrendTrade8696 Jul. 8 at 2:26 PM
$INBX Wow, this is a GREAT technical picture
0 · Reply
MaverikIT
MaverikIT Jul. 7 at 7:00 PM
$INBX +1.37 - nice few day$
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 2:02 PM
JMP Securities updates rating for Inhibrx Biosciences ( $INBX ) to Market Perform.
0 · Reply
Latest News on INBX
Inhibrx Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 7 weeks ago

Inhibrx Reports Second Quarter 2025 Financial Results

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 5 months ago

Inhibrx Reports First Quarter 2025 Financial Results

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Apr 1, 2025, 4:05 PM EDT - 6 months ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 7 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 21, 2025, 5:01 PM EST - 9 months ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Jan 13, 2025, 4:15 PM EST - 9 months ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:24 PM EST - 11 months ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 5, 2024, 11:45 AM EST - 11 months ago

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Nov 4, 2024, 4:00 PM EST - 11 months ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

Aug 27, 2024, 7:10 AM EDT - 1 year ago

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

HNRG TCBI

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 6:54 PM EDT - 1 year ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 7, 2024, 2:42 PM EDT - 1 year ago

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

Jun 5, 2024, 7:46 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

A EXAS TDOC

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 24, 2024, 4:00 PM EDT - 1 year ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 10, 2024, 6:36 PM EDT - 1 year ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

May 9, 2024, 3:36 PM EDT - 1 year ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

May 8, 2024, 4:37 PM EDT - 1 year ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 9:15 AM EST - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

Jan 23, 2024, 11:45 AM EST - 1 year ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Sanofi to Buy Rare-Disease Assets From Inhibrx

Jan 23, 2024, 5:39 AM EST - 1 year ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

Jan 23, 2024, 1:32 AM EST - 1 year ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Jan 23, 2024, 1:30 AM EST - 1 year ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Jan 23, 2024, 1:00 AM EST - 1 year ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx Announces Participation in Upcoming Scientific Conferences

Oct 18, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Andreas Halvorsen's Firm Ups Inhibrx Stake

Sep 1, 2023, 4:26 PM EDT - 2 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Inhibrx Announces $200 Million Private Placement Financing

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Announces $200 Million Private Placement Financing

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Aug 17, 2023, 4:41 PM EDT - 2 years ago

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 7, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 30, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023, 4:05 PM EDT - 2 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 26, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Inhibrx: Undercovered Company With Good Potential

Apr 13, 2023, 11:12 AM EDT - 2 years ago

Inhibrx: Undercovered Company With Good Potential

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Mar 6, 2023, 4:05 PM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Jan 4, 2023, 9:00 AM EST - 2 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Nov 16, 2022, 9:00 AM EST - 3 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 7, 2022, 4:05 PM EST - 3 years ago

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Oct 4, 2022, 8:00 AM EDT - 3 years ago

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Aug 15, 2022, 4:05 PM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Aug 8, 2022, 5:19 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance

Jun 30, 2022, 9:00 AM EDT - 3 years ago

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance

Inhibrx: Potential To Move To Registration Study With INBRX-101

Jun 10, 2022, 1:29 PM EDT - 3 years ago

Inhibrx: Potential To Move To Registration Study With INBRX-101

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

May 19, 2022, 4:05 PM EDT - 3 years ago

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

May 16, 2022, 12:42 PM EDT - 3 years ago

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

highnihilism
highnihilism Oct. 1 at 9:29 AM
$UAN CVR Partners LP Trade Count: 10 | Total $: 6.1 K | 0.01 × 90-Day Avg $: 648 | Call $: 3.3 K | Put $: 2.8 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CRDU 2X Long $CRDO Daily ETF Trade Count: 3 | Total $: 3.4 K | 0.50 × 90-Day Avg $: 6.7 K | Call $: 3.3 K | Put $: 120 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $INBX Inhibrx Biosciences Trade Count: 11 | Total $: 4.9 K | 0.24 × 90-Day Avg $: 20.8 K | Call $: 3.2 K | Put $: 1.7 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $FDP Fresh Del Monte Produce Trade Count: 9 | Total $: 3.4 K | 0.35 × 90-Day Avg $: 9.9 K | Call $: 3.2 K | Put $: 202 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
highnihilism
highnihilism Sep. 16 at 7:44 PM
IWM: Russell 2000 → $REFI Chicago Atlantic Real Estate Finance $PLOW Douglas Dynamics $INBX Inhibrx Biosciences $VIR Vir Biotechnology $RXST Rxsight
0 · Reply
DriftScale
DriftScale Sep. 15 at 10:18 AM
$INBX Steady performer; incremental growth from new product launches
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 7:46 AM
$INBX Really good write-up that perfectly summarizes INBX's present situation. So if you want to bring your INBX knowledge up to date or just discover INBX, this is required reading. https://beyondspx.com/quote/INBX/inhibrx-biosciences-unpacking-the-post-spin-off-pipeline-and-technology-edge-nasdaq-inbx#analysis
0 · Reply
MacroMotif
MacroMotif Aug. 27 at 9:47 AM
$INBX gradually climbing, but watch for sharp reversals.
0 · Reply
JarvisFlow
JarvisFlow Aug. 22 at 1:01 PM
JMP Securities updates rating for Inhibrx Biosciences ( $INBX ) to Market Perform.
0 · Reply
mitchell5150
mitchell5150 Jul. 8 at 2:32 PM
$INBX Let’s go!!!!!
0 · Reply
TrendTrade8696
TrendTrade8696 Jul. 8 at 2:26 PM
$INBX Wow, this is a GREAT technical picture
0 · Reply
MaverikIT
MaverikIT Jul. 7 at 7:00 PM
$INBX +1.37 - nice few day$
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 2:02 PM
JMP Securities updates rating for Inhibrx Biosciences ( $INBX ) to Market Perform.
0 · Reply
Armonica423
Armonica423 May. 10 at 7:11 PM
$INBX Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
justiceforb_85
justiceforb_85 May. 2 at 5:20 AM
$INBX thoughts on the probability of ozekibart being effective in chondrosarcoma?
1 · Reply
TrendTrade8696
TrendTrade8696 Apr. 7 at 3:53 PM
$INBX INBX is focusing solely on the development and commercialization of its promising oncology and rare disease therapeutic candidates. The company's clinical pipeline now includes ozekibart INBRX-109, a tetravalent death receptor 5 (DR5) agonist, and INBRX-106, a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40. Close to $12/sh in cash and LOTS of insider buying over last 10 months
0 · Reply
TrendTrade8696
TrendTrade8696 Apr. 7 at 3:32 PM
$INBX Looking at balance sheet INBX has almost $12/sh in cash.... hmmmm
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Apr. 2 at 10:10 AM
WATCHLIST APR 02 2025. $EWTX Edgewise Therapeutics Announced Topline Data Of EDG-7500 From The Phase 2 CIRRUS-HCM Four-week Trial In Participants With Obstructive Or Nonobstructive Hypertrophic Cardiomyopathy $GLSI Greenwich Lifesciences Announces Immune Response Data From FLAMINGO-01 Phase 3 Clinical Trial $AULT Autolus Therapeutics shares are trading lower after Truist Securities cut its price target on the stock from $11 to $10. $JNJ Johnson & Johnson Announces Expected Closing Date For Intra-Cellular Acquisition; To Complete Intra-Cellular Acquisition Around April 2, 2025 $INBX Inhibrx Biosciences Announces Departure Of Dr. Brendan Eckelman, Co-founder And Chief Scientific Officer And Appoints Dr. Carlos Bais And David Matly to CSO and President, Respectively
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 21 at 9:48 AM
$INBX Digging INBX's oncology pipeline. Regeneron partnership looks promising. Phase 2 data for ozekibart in mid-2025 could be a game changer. Watching closely. polished article: https://beyondspx.com/article/inhibrx-biosciences-inbx-navigating-the-oncology-and-rare-disease-landscape-with-a-robust-pipeline-and-strategic-transactions
0 · Reply
JarvisFlow
JarvisFlow Mar. 18 at 2:35 PM
Citizens Capital Markets has updated their rating for Inhibrx Biosciences ( $INBX ) to Market Perform.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 8:14 PM
$INBX Inhibrx reports Q4 EPS ($3.09) vs. ($6.93) last year Reports Q4 revenue $100,000 vs. $1.63M last year.
0 · Reply
UncleStock
UncleStock Mar. 7 at 9:02 PM
$SQNS $SNAL $GOLF $INBX suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR
0 · Reply
UncleStock
UncleStock Feb. 20 at 8:39 PM
$INBX $AISP $ROIV $IMKTA suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR
0 · Reply
UncleStock
UncleStock Feb. 13 at 6:21 PM
$IH $ROIV $RSSS $INBX suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR
0 · Reply